Financial reports
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25 Mar 24
8-K
Termination of a Material Definitive Agreement
1 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Feb 24
8-K
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8 Jan 24
8-K
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
11 Dec 23
8-K
Departure of Directors or Certain Officers
20 Nov 23
8-K
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
8-K
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
11 Sep 23
8-K
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
8-K
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
7 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Mar 23
424B3
Prospectus supplement
3 Jan 23
S-1
IPO registration
23 Dec 22
S-8
Registration of securities for employees
11 Aug 22
424B5
Prospectus supplement for primary offering
18 Mar 22
S-3
Shelf registration
10 Aug 21
424B5
Prospectus supplement for primary offering
15 Mar 21
424B5
Prospectus supplement for primary offering
11 Mar 21
S-8
Registration of securities for employees
12 Jun 20
424B5
Prospectus supplement for primary offering
3 Mar 20
Proxies
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
15 Apr 22
PRE 14A
Preliminary proxy
6 Apr 22
DEFR14A
Revised proxy
5 May 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
DEF 14A
Definitive proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
28 Mar 19
DEF 14A
Definitive proxy
28 Mar 19
DEFM14A
Proxy related to merger
14 Sep 18
Other
EFFECT
Notice of effectiveness
3 Jan 23
CORRESP
Correspondence with SEC
29 Dec 22
UPLOAD
Letter from SEC
29 Dec 22
EFFECT
Notice of effectiveness
20 Aug 21
CORRESP
Correspondence with SEC
17 Aug 21
UPLOAD
Letter from SEC
17 Aug 21
EFFECT
Notice of effectiveness
26 Jun 19
CORRESP
Correspondence with SEC
21 Jun 19
UPLOAD
Letter from SEC
20 Jun 19
CT ORDER
Confidential treatment order
1 Apr 19